Kelyniam Rebounds, Bets on Innovation Over Buyout Offer

CANTON, Conn. – March 16, 2026 – In a striking display of resilience and strategic confidence, medical device manufacturer Kelyniam Global (OTC: KLYG) has navigated a turbulent year to emerge with a significantly healthier bottom line, a game-changing product approval, and a firm rejection of an unsolicited acquisition offer. The company’s 2025 financial results reveal a story not of simple decline, but of a strategic pivot that prioritized long-term value over short-term revenue figures.

While total revenue saw an 8% decrease to $3,053,222 for the year, the more telling figure was a dramatic 85% improvement in net loss, which shrank to $(138,555) from $(920,206) in the prior year. This financial turnaround was coupled with two major strategic announcements: securing FDA 510(k) clearance for its innovative Fusion™ cranial implant and the board’s decision to turn down a buyout offer it deemed “materially inadequate.” Together, these moves paint a picture of a company betting decisively on its own technology and future.

“Despite a challenging start to last year, our team delivered a strong rebound in the second half while achieving meaningful bottom-line progress through continued expense management,” said Ross Bjella, CEO of Kelyniam Global, in the company’s official announcement.

A Tale of Two Halves

The full-year financials obscure a story of significant in-year recovery. Kelyniam entered 2025 after a record-setting 2024, which saw revenues climb nearly 25% and a return to profitability. However, the first half of 2025 proved challenging, with the company reporting a 34.7% year-over-year revenue drop in the first quarter and continued headwinds into the second. During this period, the company posted operating losses, a stark reversal from the profits of the previous year, citing investments in sales support and regulatory costs for its new product line.

Yet, the narrative shifted dramatically in the latter half of the year. The company’s ability to slash its net loss by 85% by year-end, even with the overall revenue dip, points to aggressive and successful expense controls and a powerful operational rebound. This financial discipline, combined with the elimination of one-time charges from the previous year, allowed Kelyniam to strengthen its foundation and prepare for a new phase of growth, a trend seemingly validated by a robust 84% revenue increase reported for the first quarter of 2026.

Beyond PEEK: A Leap Forward in Cranial Reconstruction

The cornerstone of Kelyniam’s confident outlook is the FDA clearance of its Fusion™ cranial and craniofacial implants. This marks a significant technological milestone, not just for the company, but for the entire field of cranial reconstruction. For the first time in the U.S., surgeons have access to a custom implant that combines the proven benefits of PEEK (Polyetheretherketone) with the regenerative properties of biphasic calcium phosphate (BCP).

The base material, PEEK, is already a gold standard in cranial implants, prized for its bone-like strength, biocompatibility, and radiolucency, which prevents interference with post-operative MRI or CT scans. Kelyniam’s innovation, developed with materials from specialty chemical company Evonik, is to infuse the PEEK with BCP, a well-known osteoconductive material that actively encourages bone growth.

This new biomaterial, VESTAKEEP® Fusion, creates a bioactive surface on the implant. Preclinical and in vitro studies have documented its remarkable efficacy, demonstrating an approximately twofold increase in bone apposition at the implant interface and a more than 30% increase in bone cell attachment compared to standard PEEK. For patients, this could mean faster, more robust healing and a more complete integration of the implant with their own bone structure.

This technology provides a distinct advantage over both traditional PEEK and metal implants. While metals like titanium are strong, they can create imaging artifacts and lack any osteoconductive properties. Kelyniam’s Fusion™ implant offers a metal-free alternative that not only provides structural support but actively participates in the healing process.

Forging an Independent Path

Perhaps the boldest signal of Kelyniam’s strategy was its disclosure that it rejected an unsolicited acquisition offer in late 2025. In a market where small, innovative medtech firms are often prime targets for larger players, Kelyniam’s board determined the preliminary cash and stock offer did not adequately reflect the company’s value. This decision speaks volumes about management’s belief in its proprietary technology and long-term growth potential.

The move comes as the medtech M&A landscape is heating up, with buyers showing a keen interest in companies with innovative, high-growth assets and clear regulatory pathways. By turning down the offer, Kelyniam is making a statement that the future value unlocked by products like the Fusion™ implant and its expanding regenerative portfolio is worth more than a premature sale.

This stand for independence suggests the company believes its rapid manufacturing capabilities and unique product offerings give it a durable competitive edge. Kelyniam specializes in the rapid production of custom implants, boasting an industry-leading 24-48 hour turnaround time from design to delivery for expedited cases. This capability is enabled by its advanced computer-aided design and manufacturing (CAD/CAM) processes, all conducted within its Canton, Connecticut facility. For surgeons and hospitals, this speed can be critical, potentially reducing patient hospital stays and allowing for more flexible surgical scheduling. The company’s patented Integrated Fixation System, which simplifies the implant securing process during surgery, further enhances its value proposition.

By combining this operational excellence with a breakthrough in biomaterial science, Kelyniam is not just recovering from a difficult year; it is actively shaping a future where it stands as an independent leader in advanced cranial reconstruction.